the staff of the Ridgewood blog
Israel , Oravax is testing an oral vaccine in preclinical trials against Covid-19 variants. The vaccine is based on an oral delivery technology that can be used to administer several protein-based therapies that would otherwise be delivered by injection. It targets three structural proteins of the novel coronavirus and should be more resistant to variants. An oral vaccine would be easier to distribute, and people would be able to self-administer it at home. Oral medications tend to have fewer side effects.